Bausch + Lomb Corp. (BLCO)

$16.75

+0.09

(+0.54%)

Market is closed - opens 7 PM, 18 Jul 2024

Performance

  • $16.40
    $16.96
    $16.75
    downward going graph

    2.09%

    Downside

    Day's Volatility :3.3%

    Upside

    1.24%

    downward going graph
  • $13.16
    $20.64
    $16.75
    downward going graph

    21.43%

    Downside

    52 Weeks Volatility :36.24%

    Upside

    18.85%

    downward going graph

Returns

PeriodBausch + Lomb Corp.Sector (Health Care)Index (Russel 2000)
3 Months
16.42%
8.2%
0.0%
6 Months
13.1%
7.5%
0.0%
1 Year
-19.28%
14.3%
0.0%
3 Years
-16.7%
16.5%
-18.2%

Highlights

Market Capitalization
5.6B
Book Value
$18.95
Earnings Per Share (EPS)
-0.96
PEG Ratio
4.87
Wall Street Target Price
25.91
Profit Margin
-7.81%
Operating Margin TTM
1.37%
Return On Assets TTM
1.08%
Return On Equity TTM
-4.69%
Revenue TTM
4.3B
Revenue Per Share TTM
12.3
Quarterly Revenue Growth YOY
18.0%
Gross Profit TTM
2.2B
EBITDA
613.0M
Diluted Eps TTM
-0.96
Quarterly Earnings Growth YOY
-0.89
EPS Estimate Current Year
0.86
EPS Estimate Next Year
1.2
EPS Estimate Current Quarter
0.07
EPS Estimate Next Quarter
0.2

Analyst Recommendation

Buy
    55%Buy
    44%Hold
    0
    0%Sell
Based on 18 Wall street analysts offering stock ratings for Bausch + Lomb Corp.(by analysts ranked 0 to 5 stars)
Based on 18 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
10
11
Hold
8
8
7
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 54.69%

Current $16.75
Target $25.91

Company Financials

FY18Y/Y Change
Revenue
3.7B
-
Net Income
710.0M
-
Net Profit Margin
19.37%
-
FY19Y/Y Change
Revenue
3.8B
↑ 3.08%
Net Income
298.0M
↓ 58.03%
Net Profit Margin
7.89%
↓ 11.48%
FY20Y/Y Change
Revenue
3.4B
↓ 9.69%
Net Income
-17.0M
↓ 105.7%
Net Profit Margin
-0.5%
↓ 8.39%
FY21Y/Y Change
Revenue
3.8B
↑ 10.35%
Net Income
182.0M
↓ 1170.59%
Net Profit Margin
4.83%
↑ 5.33%
FY22Y/Y Change
Revenue
3.8B
↑ 0.08%
Net Income
15.0M
↓ 91.76%
Net Profit Margin
0.4%
↓ 4.43%
FY23Y/Y Change
Revenue
4.1B
↑ 10.03%
Net Income
-260.0M
↓ 1833.33%
Net Profit Margin
-6.27%
↓ 6.67%
Q4 FY22Q/Q Change
Revenue
996.0M
↑ 5.73%
Net Income
-1000.0K
↓ 93.33%
Net Profit Margin
-0.1%
↑ 1.49%
Q1 FY23Q/Q Change
Revenue
931.0M
↓ 6.53%
Net Income
-88.0M
↑ 8700.0%
Net Profit Margin
-9.45%
↓ 9.35%
Q2 FY23Q/Q Change
Revenue
1.0B
↑ 11.17%
Net Income
-32.0M
↓ 63.64%
Net Profit Margin
-3.09%
↑ 6.36%
Q3 FY23Q/Q Change
Revenue
1.0B
↓ 2.71%
Net Income
-84.0M
↑ 162.5%
Net Profit Margin
-8.34%
↓ 5.25%
Q4 FY23Q/Q Change
Revenue
1.2B
↑ 16.48%
Net Income
-54.0M
↓ 35.71%
Net Profit Margin
-4.6%
↑ 3.74%
Q1 FY24Q/Q Change
Revenue
1.1B
↓ 6.31%
Net Income
-167.0M
↑ 209.26%
Net Profit Margin
-15.2%
↓ 10.6%
FY19Y/Y Change
Total Assets
11.5B
-
Total Liabilities
1.4B
-
FY20Y/Y Change
Total Assets
11.3B
↓ 1.76%
Total Liabilities
1.3B
↓ 11.0%
FY21Y/Y Change
Total Assets
10.8B
↓ 3.93%
Total Liabilities
1.4B
↑ 11.19%
FY22Y/Y Change
Total Assets
11.1B
↑ 2.97%
Total Liabilities
4.0B
↑ 184.52%
FY23Y/Y Change
Total Assets
13.4B
↑ 20.62%
Total Liabilities
6.5B
↑ 61.32%
Q4 FY22Q/Q Change
Total Assets
11.1B
↑ 4.19%
Total Liabilities
4.0B
↑ 3.64%
Q1 FY23Q/Q Change
Total Assets
11.2B
↑ 0.22%
Total Liabilities
4.1B
↑ 1.83%
Q2 FY23Q/Q Change
Total Assets
11.3B
↑ 1.31%
Total Liabilities
4.3B
↑ 4.08%
Q3 FY23Q/Q Change
Total Assets
13.1B
↑ 15.49%
Total Liabilities
6.2B
↑ 44.34%
Q4 FY23Q/Q Change
Total Assets
13.4B
↑ 2.86%
Total Liabilities
6.5B
↑ 5.45%
Q1 FY24Q/Q Change
Total Assets
13.3B
↓ 1.11%
Total Liabilities
6.6B
↑ 0.64%
FY18Y/Y Change
Operating Cash Flow
763.0M
-
Investing Cash Flow
-74.0M
-
Financing Cash Flow
-665.0M
-
FY19Y/Y Change
Operating Cash Flow
799.0M
↑ 4.72%
Investing Cash Flow
-186.0M
↑ 151.35%
Financing Cash Flow
-606.0M
↓ 8.87%
FY20Y/Y Change
Operating Cash Flow
522.0M
↓ 34.67%
Investing Cash Flow
-256.0M
↑ 37.63%
Financing Cash Flow
-232.0M
↓ 61.72%
FY21Y/Y Change
Operating Cash Flow
873.0M
↑ 67.24%
Investing Cash Flow
-214.0M
↓ 16.41%
Financing Cash Flow
-712.0M
↑ 206.9%
FY22Y/Y Change
Operating Cash Flow
345.0M
↓ 60.48%
Investing Cash Flow
-215.0M
↑ 0.47%
Financing Cash Flow
81.0M
↓ 111.38%
Q4 FY22Q/Q Change
Operating Cash Flow
159.0M
↑ 488.89%
Investing Cash Flow
-90.0M
↑ 83.67%
Financing Cash Flow
-7.0M
↓ 93.58%
Q1 FY23Q/Q Change
Operating Cash Flow
-56.0M
↓ 135.22%
Investing Cash Flow
-64.0M
↓ 28.89%
Financing Cash Flow
91.0M
↓ 1400.0%
Q2 FY23Q/Q Change
Operating Cash Flow
-24.0M
↓ 57.14%
Investing Cash Flow
-28.0M
↓ 56.25%
Financing Cash Flow
90.0M
↓ 1.1%
Q3 FY23Q/Q Change
Operating Cash Flow
48.0M
↓ 300.0%
Investing Cash Flow
-1.9B
↑ 6621.43%
Financing Cash Flow
1.8B
↑ 1912.22%

Technicals Summary

Sell

Neutral

Buy

Bausch + Lomb Corp. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Bausch + Lomb Corp.
Bausch + Lomb Corp.
11.51%
13.1%
-19.28%
-16.7%
-16.7%
Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
1.86%
22.05%
23.79%
40.96%
151.01%
Resmed Inc.
Resmed Inc.
-1.69%
21.14%
-6.33%
-18.44%
67.07%
Becton, Dickinson And Company
Becton, Dickinson And Company
-0.88%
-1.54%
-10.11%
-6.69%
-8.4%
West Pharmaceutical Services Inc
West Pharmaceutical Services Inc
-2.07%
-3.06%
-14.21%
-11.29%
169.96%
Alcon Ag
Alcon Ag
2.05%
18.06%
7.1%
32.38%
48.6%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Bausch + Lomb Corp.
Bausch + Lomb Corp.
914.0
NA
4.87
0.86
-0.05
0.01
NA
18.95
Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
78.78
78.78
7.13
6.29
0.16
0.08
NA
39.37
Resmed Inc.
Resmed Inc.
31.54
31.54
1.75
7.73
0.22
0.12
0.01
31.52
Becton, Dickinson And Company
Becton, Dickinson And Company
48.41
48.41
1.34
13.04
0.05
0.03
0.02
88.74
West Pharmaceutical Services Inc
West Pharmaceutical Services Inc
42.18
42.18
6.72
7.76
0.21
0.11
0.0
36.72
Alcon Ag
Alcon Ag
42.56
42.56
4.59
3.07
0.05
0.02
0.0
42.13
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Bausch + Lomb Corp.
Bausch + Lomb Corp.
Buy
$5.6B
-16.7%
914.0
-7.81%
Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
Buy
$155.1B
151.01%
78.78
27.16%
Resmed Inc.
Resmed Inc.
Buy
$30.2B
67.07%
31.54
20.91%
Becton, Dickinson And Company
Becton, Dickinson And Company
Buy
$65.3B
-8.4%
48.41
6.76%
West Pharmaceutical Services Inc
West Pharmaceutical Services Inc
Buy
$23.4B
169.96%
42.18
19.42%
Alcon Ag
Alcon Ag
Buy
$44.3B
48.6%
42.56
10.96%

Insights on Bausch + Lomb Corp.

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 1.17B → 1.09B (in $), with an average decrease of 6.3% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -54.0M → -167.0M (in $), with an average decrease of 209.3% per quarter

  • Vs ISRG

    In the last 1 year, Intuitive Surgical, Inc. has given 23.8% return, outperforming this stock by 43.1%

Institutional Holdings

  • Fidelity International Ltd

    2.33%
  • Goldentree Asset Management LP

    1.34%
  • Maple Rock Capital Partners, Inc.

    1.07%
  • ICAHN CARL C

    1.00%
  • River Road Asset Management, LLC

    0.54%
  • Alberta Investment Management Corp

    0.45%

Company Information

bausch and lomb corp is a renewables and environment company based out of calle laguna del marquesado nª 19, nave 16 edificio adriana 1ª planta, polígono industrial la resina (villaverde), madrid, community of madrid, spain.

Organization
Bausch + Lomb Corp.
Employees
13300
CEO
Mr. Osama A. Eldessouky
Industry
Healthcare

FAQs